# A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Source: https://onco.cc/trials/nct03899792/  
OnCo record `nct03899792` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Selpercatinib in thyroid cancer and sarcomas, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors is a phase 1/2 interventional study registered as NCT03899792 by Eli Lilly and Company, with 36 participants enrolled, started 2019-06-13 and due to reach its primary completion in 2024-11-08. Interventions recorded: Selpercatinib. Conditions listed: Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: LIBRETTO-121
- Tags: ctgov-ingest
- Registry id: NCT03899792
- Phase: 1/2
- Setting: A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
- Sponsor: Eli Lilly and Company
- Enrolled: 36
- Outcomes: Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study: Cohort 1 (Phase 2): MTC Group 60% vs Cohort 2 (Phase 2): PTC Group 53.3% vs Cohort 3 (Phase 2): Other Cancer Group 33.3%

## Sources

- ClinicalTrials.gov NCT03899792: https://clinicaltrials.gov/study/NCT03899792

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Selpercatinib](https://onco.cc/drugs/selpercatinib/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct03899792.json